Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...

IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

The future of the largest film and TV studio in the west of England is set to be discussed at a meeting later. Bristol City Council, which owns the Bottle Yard Studios in Hengrove, is looking at ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...